Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > More good news for SaNOtize more good news for us....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(273)
•••
Comment by Dude51on Apr 17, 2021 9:58am
138 Views
Post# 33016848

RE:RE:More good news for SaNOtize more good news for us....

RE:RE:More good news for SaNOtize more good news for us....RE:More good news for SaNOtize more good news for us....
This is the first company I've ever heard of where investors think good news for the competition benefits them.


That's because you think this is a shell company to begin with Scotty.  Let me explain loser, you see SaNOtize has one product to our many. That one product is something we can produce to compete with SaNOtize and if you had read the Andrew Salzman interview on the Claritas Investors website you would come to the definite conclusion that the Claritas nasel spray would be superior to the SaNOtize product. So taking that into account who is a public company? We are and who has the better product? We do. Who has multiple avenues for revenues, we do. There are many other attributes that Claritas can claiim, SaNOtize has a nasel spray and its licenced in Israel and New Zealand and is being introduced as I type to their populations and now India is coming on line?
To me that is a WOW factor for us. To you were just a shell company which is rather funny with all the news that has come out since the unhalt. Keep your head in the sand Scotty, the rest of us investors will soon be sitting on that sand.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities